| Joseph Raymond Pesce, MD | |
|
4699 Main St, Suite 212, Bridgeport, CT 06606 | |
| (203) 372-8949 | |
| (203) 374-9296 |
| Full Name | Joseph Raymond Pesce |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 58 Years |
| Location | 4699 Main St, Bridgeport, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548378813 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 013383 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associates In Dermatology Llc | 0840205910 | 2 |
News Archive
Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.
Investing and innovating in ways that break through cost, quality and access barriers to health for individuals and entire health systems, GE Healthcare is highlighting an advanced portfolio of molecular imaging technologies at the 58th annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio.
Mazor Robotics Ltd., a leading developer of innovative bone mounted surgical robotic guidance systems, today entered into two strategic agreements with Medtronic plc (NYSE: MDT). One agreement is a two-stage, multi-faceted, commercial agreement for co-promotion, co-development and, upon meeting certain milestones, potential global distribution of certain Mazor products. The second agreement is for an equity investment by Medtronic in Mazor.
New research discovered that tocilizumab is more effective than rituximab in achieving low disease activity in patients with rheumatoid arthritis whose synovial tissue show a low level of B cell infiltration and did not respond to conventional synthetic disease-modifying anti-rheumatic drugs (conventional synthetic DMARDs) or tumor necrosis factor inhibitors first.
Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics' products that incorporate Biosearch's proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics' infectious disease tests for sale in underdeveloped countries.
› Verified 8 days ago
| Entity Name | Associates In Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790842227 PECOS PAC ID: 0840205910 Enrollment ID: O20060210000048 |
News Archive
Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.
Investing and innovating in ways that break through cost, quality and access barriers to health for individuals and entire health systems, GE Healthcare is highlighting an advanced portfolio of molecular imaging technologies at the 58th annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio.
Mazor Robotics Ltd., a leading developer of innovative bone mounted surgical robotic guidance systems, today entered into two strategic agreements with Medtronic plc (NYSE: MDT). One agreement is a two-stage, multi-faceted, commercial agreement for co-promotion, co-development and, upon meeting certain milestones, potential global distribution of certain Mazor products. The second agreement is for an equity investment by Medtronic in Mazor.
New research discovered that tocilizumab is more effective than rituximab in achieving low disease activity in patients with rheumatoid arthritis whose synovial tissue show a low level of B cell infiltration and did not respond to conventional synthetic disease-modifying anti-rheumatic drugs (conventional synthetic DMARDs) or tumor necrosis factor inhibitors first.
Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics' products that incorporate Biosearch's proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics' infectious disease tests for sale in underdeveloped countries.
› Verified 8 days ago
| Entity Name | Integrated Dermatology Of Clinton,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457728883 PECOS PAC ID: 7416257381 Enrollment ID: O20151125000408 |
News Archive
Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.
Investing and innovating in ways that break through cost, quality and access barriers to health for individuals and entire health systems, GE Healthcare is highlighting an advanced portfolio of molecular imaging technologies at the 58th annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio.
Mazor Robotics Ltd., a leading developer of innovative bone mounted surgical robotic guidance systems, today entered into two strategic agreements with Medtronic plc (NYSE: MDT). One agreement is a two-stage, multi-faceted, commercial agreement for co-promotion, co-development and, upon meeting certain milestones, potential global distribution of certain Mazor products. The second agreement is for an equity investment by Medtronic in Mazor.
New research discovered that tocilizumab is more effective than rituximab in achieving low disease activity in patients with rheumatoid arthritis whose synovial tissue show a low level of B cell infiltration and did not respond to conventional synthetic disease-modifying anti-rheumatic drugs (conventional synthetic DMARDs) or tumor necrosis factor inhibitors first.
Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics' products that incorporate Biosearch's proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics' infectious disease tests for sale in underdeveloped countries.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Raymond Pesce, MD 4699 Main St, Suite 212, Bridgeport, CT 06606 Ph: (203) 372-8949 | Joseph Raymond Pesce, MD 4699 Main St, Suite 212, Bridgeport, CT 06606 Ph: (203) 372-8949 |
News Archive
Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced first patient enrollment in the TOCCASTAR (TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation) clinical study at Na Homolce Hospital, Prague, Czech Republic, by study investigator Petr Neuzil, M.D.
Investing and innovating in ways that break through cost, quality and access barriers to health for individuals and entire health systems, GE Healthcare is highlighting an advanced portfolio of molecular imaging technologies at the 58th annual meeting of the Society of Nuclear Medicine (SNM), June 4-8, in San Antonio.
Mazor Robotics Ltd., a leading developer of innovative bone mounted surgical robotic guidance systems, today entered into two strategic agreements with Medtronic plc (NYSE: MDT). One agreement is a two-stage, multi-faceted, commercial agreement for co-promotion, co-development and, upon meeting certain milestones, potential global distribution of certain Mazor products. The second agreement is for an equity investment by Medtronic in Mazor.
New research discovered that tocilizumab is more effective than rituximab in achieving low disease activity in patients with rheumatoid arthritis whose synovial tissue show a low level of B cell infiltration and did not respond to conventional synthetic disease-modifying anti-rheumatic drugs (conventional synthetic DMARDs) or tumor necrosis factor inhibitors first.
Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics' products that incorporate Biosearch's proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics' infectious disease tests for sale in underdeveloped countries.
› Verified 8 days ago
Dr. Kenneth Joseph Maiocco, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4639 Main St, Bridgeport, CT 06606 Phone: 203-374-5546 Fax: 203-371-4056 | |
Dr. Edward Isaac Herman, M.D., PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2800 Main St, Bridgeport, CT 06606 Phone: 203-576-6000 | |
Dr. Jeremy Ethan Moss, M.D., PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4639 Main St, Bridgeport, CT 06606 Phone: 203-374-5546 Fax: 203-371-4056 | |
Dr. Katherine Jane Pesce, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4699 Main St, Suite 212, Bridgeport, CT 06606 Phone: 203-372-8949 Fax: 203-372-9296 |